Kiniksa Pharmaceuticals Email Format
Biotechnology Research
・
201-500 employees
・
Lexington, MA, USA
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for debilitating diseases with unmet medical needs, particularly cardiovascular indications.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@kiniksa.com
Company Overview
Industry
Biotechnology Research
Founded
2015
Headquarters
Lexington, MA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Website
Key Executives
Sanj K. Patel (Chairman & CEO), Mark Ragosa (Executive Vice President, Chief Financial Officer), Ross Moat (Executive Vice President, Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals uses the firstinitiallast format, so Jane Smith would be jsmith@kiniksa.com.
What FDA-approved therapy does Kiniksa Pharmaceuticals currently commercialize?
Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), the first and only FDA-approved therapy for recurrent pericarditis. In 2026, the company projects ARCALYST net product revenue of between $930 million and $945 million.
Where is Kiniksa Pharmaceuticals headquartered and how large is its team?
Kiniksa Pharmaceuticals is headquartered in Lexington, MA, and employs around 380 people. You can use Clay to build a targeted prospect list or find verified contacts at the company.
Who leads Kiniksa Pharmaceuticals as CEO?
Kiniksa Pharmaceuticals is led by Sanj K. Patel, who serves as Chairman and CEO. The executive team also includes Mark Ragosa as Chief Financial Officer and Ross Moat as Chief Operating Officer.
Does Kiniksa Pharmaceuticals have any clinical-stage assets beyond its approved cardiovascular product?
Yes, Kiniksa Pharmaceuticals has several clinical-stage candidates including mavrilimumab, which is being evaluated in rare cardiovascular diseases, and KPL-404, a Phase 2 asset targeting rheumatoid arthritis through the CD40/CD154 pathway.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating